Melidou Angeliki, Broberg Eeva
European Center for Disease Prevention and Control (ECDC), Stockholm, Sweden.
European Center for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Vaccine. 2017 Sep 5;35(37):4828-4835. doi: 10.1016/j.vaccine.2017.07.057. Epub 2017 Aug 7.
During the European 2016/17 influenza season, A(H3N2) viruses have predominated and the majority clustered in genetic subclade 3C.2a1. Genetic analyses showed that circulating viruses have undergone considerable genetic diversification of the haemagglutinin gene from the current vaccine virus A/Hong Kong/4801/2014 (clade 3C.2a), but the antigenic data that is limited by the challenges with the antigenic characterisation of currently circulating A(H3N2) viruses, showed no clear evidence of antigenic change. The recommended A(H3N2) vaccine component for the northern hemisphere 2017/18 influenza season remained unchanged. However, early and mid-season vaccine effectiveness (VE) estimates were suggestive of reduced VE against A(H3N2) viruses.
在2016/17年欧洲流感季期间,A(H3N2)病毒占主导地位,且大多数聚集在遗传亚分支3C.2a1中。基因分析表明,目前流行的病毒与当前疫苗病毒A/香港/4801/2014(3C.2a分支)相比,血凝素基因发生了相当大的基因多样化,但由于目前流行的A(H3N2)病毒抗原特性鉴定面临挑战,有限的抗原数据显示没有明显的抗原变化证据。2017/18年北半球流感季推荐的A(H3N2)疫苗成分保持不变。然而,季初和季中疫苗效力(VE)估计表明针对A(H3N2)病毒的VE有所降低。